Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.52USD
−19.38 MUSD
0.00USD
24.01 M
About DiaMedica Therapeutics Inc.
Sector
Industry
CEO
Rick John Pauls
Website
Headquarters
Minneapolis
Founded
2000
FIGI
BBG000LP4YD7
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DMAC is 4.37 USD — it has increased by 0.92% in the past 24 hours. Watch DiaMedica Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange DiaMedica Therapeutics Inc. stocks are traded under the ticker DMAC.
DMAC stock has risen by 2.09% compared to the previous week, the month change is a 5.52% rise, over the last year DiaMedica Therapeutics Inc. has showed a 102.31% increase.
We've gathered analysts' opinions on DiaMedica Therapeutics Inc. future price: according to them, DMAC price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch DMAC chart and read a more detailed DiaMedica Therapeutics Inc. stock forecast: see what analysts think of DiaMedica Therapeutics Inc. and suggest that you do with its stocks.
DMAC reached its all-time high on Aug 7, 2012 with the price of 44.94 USD, and its all-time low was 0.81 USD and was reached on Dec 5, 2014. View more price dynamics on DMAC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DMAC stock is 7.18% volatile and has beta coefficient of 1.08. Track DiaMedica Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is DiaMedica Therapeutics Inc. there?
Today DiaMedica Therapeutics Inc. has the market capitalization of 186.38 M, it has increased by 0.58% over the last week.
Yes, you can track DiaMedica Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
DiaMedica Therapeutics Inc. is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
DMAC earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.16 USD resulting in a 17.02% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about DiaMedica Therapeutics Inc. earnings.
DiaMedica Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
DMAC net income for the last quarter is −5.12 M USD, while the quarter before that showed −5.15 M USD of net income which accounts for 0.62% change. Track more DiaMedica Therapeutics Inc. financial stats to get the full picture.
No, DMAC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 19.00 employees. See our rating of the largest employees — is DiaMedica Therapeutics Inc. on this list?
Like other stocks, DMAC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DiaMedica Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DiaMedica Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DiaMedica Therapeutics Inc. stock shows the buy signal. See more of DiaMedica Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.